Ultragenyx Pharmaceutical Inc. RARE
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. 10-K, Item 1
- Employees
- 1,371
- Headquarters
- Novato, CA
- Next results
- around Jan 11, 2027
RARE among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
16 new risk paragraphs. 10-K filed Feb 18, 2026 against Feb 19, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +29.5% ($122.0M to $158.0M) vs revenue +20.2% ($560.0M to $673.0M), +9.3 pts apart
-
Cash from operations −$466.0M vs net income −$575.0M (FY ending Dec 31, 2025)
-
Inventory +15.6% ($45.0M to $52.0M) vs revenue +20.2% ($560.0M to $673.0M), -4.6 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Liabilities for sales of future royalties
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
16 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
Our future financial performance depends on the successful commercialization of our products and product candidates.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
As we increase the number and range of our commercialized products, particularly as we prepare for launches of our first gene therapy products, we will need to expand our commercial and support teams to include additional expertise in those products. We may also experience additional complexities in our sales process and strategy and…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints. Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $363.3M | $434.0M | $560.0M | $673.0M |
| Net income | −$707.4M | −$607.0M | −$569.0M | −$575.0M |
| Operating cash flow | −$380.5M | −$475.0M | −$414.0M | −$466.0M |
| Free cash flow | −$496.6M | −$519.0M | −$421.0M | −$472.0M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$673.0M ▲ 20.2% in FY2025−$575.0M in FY2025−$472.0M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 3, 2026Acquisition or sale of assets completed, Quarterly results, Restructuring or exit costs 8-K items 2.01, 2.02, 2.05
-
8-KOct 19, 2026Other events 8-K item 8.01
About the company
Ultragenyx Pharmaceutical Inc., Novato, CA · from the 10-K filed Feb 18, 2026
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph. D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics.
- Headquarters
- Novato, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 1,371 total employees, of which 916 are in research and development and 455 are in sales, general, and administrative" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 18, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.